top of page
About us

DIVERCHIM is a Small Molecule Drug Substance CDMO which focuses on developing and manufacturing high added-value ingredients: 

  • Drug candidates APIs

  • APIs for Orphan Drugs and Rare Diseases

  • Radiopharmaceutical Precursors

  • Niche specialty chemicals​​

  • Emergency medications

More than 20 years serving the development of New Chemical Entities​,

from a CRO to a CDMO

DIVERCHIM - Our History.png
Pharmaceuticals

Pharmaceuticals

Cosmetics

Cosmetics

Specialty Chemicals

Specialty Chemicals

Diagnostics

Diagnostics

Memberships

Our values

Memberships

DIVERCHIM is highly committed in running its business with high level of ethical considerations and developing manufacturing processes that are environmentally responsible.

Safety

Gender Equality

45% 
55% 

Certification in progress

YB.png

Yasmine

Bencheikh

HSE Manager

CB.png

Claire

Brayer

Office Manager

BC.png

Bruno

Dudot

Head of Large Scale Production

BF0.png

Benoît 

Folléas

CSO, Head of Project

Management

FL.png

Fabien

LAJUS

Head of QC Lab. And Analytical Development

JL.png

Jessica

Le Manac'h

Head of HR and Accounting

FM.png

François

Macarez

CEO

CN.png

Cédric

Ngoulou

Head of Purchasing

CP.png

Caroline

Perrain

QA and Regulatory Affairs Director

Solutions

Comprehensive offering, from Preclinical stage to Commercial, dedicated to the

development and manufacturing of: 

  • Small molecule APIs (including RSM and advanced intermediates)

  • Radiopharmaceutical precursors

  • GMP excipients and Linkers

  • Polymers, Nano-lipids and Hydrogels

Services
Development phase

Additional services include:

  • Lyophilization and Solid aliquotation of Radiopharmaceutical precursors

  • Reference standards

  • Standalone analytics

•  Team of 5 lead by QA Director, Org. chemist by training with 20-year experience in QA

•  ICHQ7 based quality system

•  GMP certification of the site since 2015

•  Last audit: July-22

•  Mock inspection Oct.- 2021(site registered by FDA since 2021)

•  PAI expected Q4 2024 – Q1 2025

•  DMF files submitted & accepted (EU+Switzerland + USA): 5

•  DMF files to be submitted: 10

•Project management Director, member of Comex team

•Nomination of a dedicated PM at the start-up of each project

•Project team includes experts of all services to ensure a smooth execution to comply with customer’s request

•Management of activities (Route  scouting, Developments, Validation,  Stability studies,  Production) handled by a PM

•The PM  is the privileged contact of the customer during the whole product life cycle

State-of-the-art 3000 m² facility built in 2013 including:

  • Our facility is strategically located just 20 kilometers north of Paris, near the Roissy-Charles de Gaulle airport

  • This prime location provides us with exceptional connectivity, allowing for efficient logistics and accessibility to key international hubs

Capabilities
Special Features
Lyophilization (Dispensing and Freeze-Drying capabilities)

“Ultra-clean” vials preparation in dedicated cGMP area

 

Development studies:

•Identification of CPP/KPP/nCPP

•Determination of PAR/NOR

•Ensure process robustness and GMP compliance

Current capacities:

- 400 2R Vials / run

- 180 10R vials / run

Additional capacities (investment in progress – operational T2/T3 2024):

- 1100 2R Vials / run

- 310 10R vials / run

(Dispensing and Freeze-Drying capabilities)

“Ultra-clean” vials preparation in dedicated cGMP area

 

Development studies:

  • Identification of CPP/KPP/nCPP

  • Determination of PAR/NOR

  • Ensure process robustness and GMP compliance

Current capacities (2 equipment):

  • 400 / 1100 2R Vials / run

  • 180 / 310 10R vials / run

News

Let's meet!

  • LinkedIn

See it on LinkedIn

Contact
bottom of page